These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30167527)

  • 1. Drugs and Devices: Comparison of European and U.S. Approval Processes.
    Van Norman GA
    JACC Basic Transl Sci; 2016 Aug; 1(5):399-412. PubMed ID: 30167527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs.
    Van Norman GA
    JACC Basic Transl Sci; 2016 Apr; 1(3):170-179. PubMed ID: 30167510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Difference between Approval Processes for Medicinal Products and Medical Devices in Europe.
    Marshall J; Morrill K; Gobbe M; Blanchard L
    Ophthalmologica; 2021; 244(5):368-378. PubMed ID: 34062546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study.
    Hwang TJ; Sokolov E; Franklin JM; Kesselheim AS
    BMJ; 2016 Jun; 353():i3323. PubMed ID: 27352914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea.
    Kim JH; Kwon S; Seol JE; Kim MH; Kim SD
    Ther Innov Regul Sci; 2024 Sep; 58(5):796-806. PubMed ID: 38717522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
    Oner ZG; Michel SLJ; Polli JE
    Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
    Joppi R; Bertele V; Vannini T; Garattini S; Banzi R
    Br J Clin Pharmacol; 2020 Jan; 86(1):170-174. PubMed ID: 31657044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J; Park J; Song SY; Kim E
    Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-comparison of cancer drug approvals at three international regulatory agencies.
    Samuel N; Verma S
    Curr Oncol; 2016 Oct; 23(5):e454-e460. PubMed ID: 27803605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the renewed European Medical Device Regulations in the frame of the non - EU regulatory landscape during the COVID facilitated change.
    Kanti SPY; Csóka I; Adalbert L; Jójárt-Laczkovich O
    J Pharm Sci; 2022 Oct; 111(10):2674-2686. PubMed ID: 35872025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal regulation of the production and trade of medical devices and medical equipment in the EU and US: experience for Ukraine.
    Pashkov V; Kotvitska A; Harkusha A
    Wiad Lek; 2017; 70(3 pt 2):614-618. PubMed ID: 28713093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiology devices and the regulatory approval process within the U.S. FDA and abroad.
    Selzman KA; Patel H; Cavanaugh K
    J Interv Card Electrophysiol; 2019 Nov; 56(2):173-182. PubMed ID: 31418099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.